This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for ...
European Commission approval enables 2 mg/kg Q4W pegunigalsidase alfa for stable, ERT-treated adults, extending infusion intervals from Q2W to Q4W to lessen cumulative treatment burden. Evidence ...
In this study, the duration of enzyme induction provoked by unlabelled lactose ureide (LU) in orocaecal transit time (OCTT) measurements with lactose-[13 C]ureide (13 C-LU) was evaluated. Without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results